

**Acronyms and abbreviations commonly used by the BactiVac Network**

<b>AMR</b>	Antimicrobial resistance
<b>AREF</b>	African Research Excellence Fund
<b>AVAREF</b>	African Vaccine Regulatory Forum
<b>BBSRC</b>	Biotechnology and Biological Sciences Research Council, United Kingdom
<b>BEIS</b>	Department for Business, Energy and Industrial Strategy, United Kingdom
<b>BMGF</b>	Bill & Melinda Gates Foundation
<b>BoD</b>	Burden of disease
<b>BoED</b>	Burden of Enteric Disease
<b>BSI</b>	British Society of Immunology
<b>CEPI</b>	Coalition for Epidemic Preparedness and Innovation
<b>CHIM</b>	Controlled human infection model
<b>CMO</b>	Chief Medical Officer
<b>CoG</b>	Cost of goods
<b>CoP</b>	Correlates of protection
<b>CSR</b>	Comprehensive spending review
<b>CTC</b>	Controlled temperature chain
<b>DCVMN</b>	Developing Country Vaccine Manufacturers' Network
<b>DHSC</b>	Department of Health and Social Care, UK
<b>EDCTP</b>	The European and Developing Countries Clinical Trials Partnership
<b>ETEC</b>	Enterotoxigenic E. coli
<b>ECVP</b>	Evidence Considerations for Vaccine Policy
<b>EPI</b>	Expanded Programme on Immunization
<b>EVI</b>	European Vaccine Initiative
<b>FCDO</b>	Foreign, Commonwealth and Development Office, United Kingdom

<b>FDI</b>	Foreign Direct Investment
<b>FVVA</b>	The Full Value of Vaccine Assessments
<b>GAMRIF</b>	The Global AMR Innovation Fund, United Kingdom
<b>GAS</b>	Group A Streptococcus
<b>GAVI</b>	Gavi, the Vaccine Alliance
<b>GBS</b>	Group B Streptococcus
<b>GVIRF</b>	Global Vaccine and Immunization Research Forum
<b>HIC</b>	High Income Countries
<b>Hic-Vac</b>	The Human Challenge Model Network
<b>IA2030</b>	Immunization Agenda 2030
<b>IFPMA</b>	International Federation of Pharmaceutical Manufacturers and Associations
<b>iiCON</b>	Infection Innovation Consortium
<b>IMPRINT</b>	Immunising pregnant women and infants Network
<b>iNTS</b>	Invasive non-typhoidal salmonella
<b>IUIS</b>	International Union of Immunological Societies
<b>IVVN</b>	The International Veterinary Vaccinology Network
<b>JPIAMR</b>	The Joint Programming Initiative on Antimicrobial Resistance
<b>LMIC</b>	Low- and middle-income countries
<b>mAb</b>	Monoclonal antibody
<b>MDV</b>	Multidose vial
<b>MicrobioSoc</b>	Microbiology Society, UK
<b>MI4A</b>	Market Information for Access to Vaccines
<b>MRC</b>	Medical Research Council, United Kingdom
<b>NAB</b>	Network Advisory Board
<b>NIHR</b>	National Institute for Health and Care Research, United Kingdom
<b>NITAG</b>	National Immunization Technical Advisory Group
<b>NMOB</b>	Network Management Oversight Board

<b>NOMG</b>	Network Operations Management Group
<b>NRA</b>	National Regulatory Authority
<b>NTD</b>	Neglected Tropical Diseases
<b>NTS</b>	Nontyphoidal salmonellosis
<b>ODA</b>	Official Development Assistance
<b>OUCRU</b>	The Oxford University Clinical Research Unit
<b>PAVM</b>	Partnership for African Vaccine Manufacturing
<b>PDVAC</b>	WHO Product Development for Vaccines Advisory Committee
<b>PDR</b>	WHO Unit of Vaccine Product and Delivery Research
<b>POSTnote</b>	UK Parliament four-page briefing reviewing emerging areas of research
<b>PPC</b>	Preferred product characteristics
<b>PQ</b>	WHO prequalification (of vaccines)
<b>SDV</b>	Single dose vial
<b>SFA</b>	Science for Africa Foundation
<b>SAGE</b>	WHO Strategic Advisory Group of Experts (on immunization)
<b>TPP</b>	Target product profile
<b>TRANSVAC2</b>	European vaccine research and development (R&D) infrastructure project
<b>UKRI</b>	UK Research and Innovation
<b>UoB</b>	University of Birmingham, UK
<b>VALIDATE</b>	The VALIDATE Network - Vaccine development for complex intracellular neglected pathogens
<b>VIPS</b>	The Vaccine Innovation Prioritisation Strategy
<b>VIS</b>	(Gavi) Vaccine Investment Strategy
<b>VMIC</b>	Vaccine Manufacturing and Innovation Centre, United Kingdom
<b>VTF</b>	Vaccine Task Force
<b>VVM</b>	Vaccine vial monitor
<b>VVP</b>	Vaccine value profile
<b>WHO</b>	World Health Organisation